
According to Benzinga Pro data, during Q4, Evoke Pharma (NASDAQ:EVOK) posted sales of $360.57 thousand. Earnings were up 15.08%, but Evoke Pharma still reported an overall loss of $1.67 million. Evoke Pharma collected $930.45 thousand in revenue during Q3, but reported earnings showed a $1.97 million loss.